Immunoscience India Profile
Key Indicators
- Authorised Capital ₹ 10.95 Cr
as on 13-12-2024
- Paid Up Capital ₹ 10.46 Cr
as on 13-12-2024
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Revenue %
(FY 2018)
- Net Worth 5.93%
(FY 2018)
- Total Assets 16.60%
(FY 2018)
About Immunoscience India
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 10.95 Cr and a paid-up capital of Rs 10.46 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Immunoscience India Private Limited India is Ashutosh Tiwari as COMPANY SECRETARY. Sateesh Apte, Amrut Kare, and Atul Tarade serve as directors at the Company.
- CIN/LLPIN
U73100PN2009FTC134231
- Company No.
134231
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
01 Jul 2009
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Immunoscience India Private Limited offer?
Immunoscience India Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Rapid Test Kit.
Who are the key members and board of directors at Immunoscience India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ashutosh Tiwari | Company Secretary | 09-Mar-2023 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sateesh Apte  | Director | 01-Jul-2009 | Current |
| Amrut Kare | Director | 01-Jul-2009 | Current |
| Atul Tarade | Director | 26-Dec-2017 | Current |
Financial Performance of Immunoscience India.
Immunoscience India Private Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth moved up by a moderate rise of 5.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Immunoscience India?
In 2018, Immunoscience India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Roboscience India Private LimitedActive 12 years 7 monthsSateesh Apte and Amrut Kare are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Immunoscience India?
Unlock and access historical data on people associated with Immunoscience India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immunoscience India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immunoscience India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
